Understanding how a specific protein regulates lung inflammation and immunity
Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases
This study is looking at a protein called PDLIM2 to see how it helps control a molecule involved in lung inflammation and diseases, with the hope of finding new treatments for people with lung conditions like cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11044070 on NIH RePORTER |
What this research studies
This research investigates the role of the protein PDLIM2 in regulating NF-kappaB, a key player in lung inflammation and diseases. By examining how PDLIM2 selectively degrades the pathogenic form of NF-kappaB while preserving its physiological function, the study aims to develop targeted therapies for lung conditions. The approach includes using mouse models to simulate human lung cancer and assess the therapeutic potential of manipulating PDLIM2 activity. Patients may benefit from insights that could lead to new treatments for lung diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with lung diseases, particularly those with acute lung injury or lung cancer.
Not a fit: Patients with non-lung-related conditions or those without any form of lung disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for lung diseases, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting NF-kappaB pathways, indicating potential for success with this novel approach.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Qu, Zhaoxia — University of Southern California
- Study coordinator: Qu, Zhaoxia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.